The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has refused marketing authorization to quizartinib for the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with a FLT3-internal tandem duplication (ITD).1,2 Having reviewed the data presented, the EMA CHMP felt that despite marginal improvement in overall survival (OS), the study had limitations that did not allow the efficacy of quizartinib to be demonstrated sufficiently for approval. They concluded that the benefits did not outweigh the risks and refused the marketing authorization.1
In May 2019, quizartinib was also rejected by the United States (US) Food & Drug Administration (FDA). The FDA Oncologic Drug Advisory Committee voted 8–3 against approval of the new drug application (NDA) and raised questions regarding the generalizability and credibility of the data.3 Quizartinib had previously been granted orphan drug designation by the EMA and breakthrough therapy designation by the FDA.4,5
The results from the QuANTUM-R trial, which assessed the value of quizartinib compared to investigator’s choice of salvage chemotherapy, were recently published in Lancet Oncology.
Given as quizartinib vs salvage chemotherapy
This study concluded quizartinib monotherapy conferred a survival benefit compared to salvage chemotherapy, with a manageable safety profile for patients with FLT3-ITD R/R AML.
The ongoing QuANTUM-First study (NCT02668653) is evaluating quizartinib plus standard chemotherapy followed by quizartinib monotherapy will benefit patients with newly diagnosed AML.
References